Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: Barbara Bullard who wrote (964)	9/1/1999 10:13:00 AM
From: jerryriti	Read Replies (2) \| Respond to of 1728

Tuesday August 31, 9:30 pm Eastern Time Company Press Release SOURCE: Affymetrix, Inc. Affymetrix Introduces GeneChip(R) HuSNP(TM) Mapping Assay New Array-Based Assay Provides Parallel Interrogation of Single Nucleotide Polymorphisms (SNPs) Distributed Across the Human Genome SANTA CLARA, Calif., Aug. 31 /PRNewswire/ -- Affymetrix, Inc. (Nasdaq: AFFX - news) introduced today the GeneChip© HuSNP(TM) Mapping Assay, an integrated solution for generating genotypes needed for genetic linkage mapping. Central to the assay is a new GeneChip HuSNP probe array, containing oligonucleotides of known sequence enabling simultaneous interrogation of nearly 1500 single nucleotide polymorphisms (SNPs) covering all 22 autosomes and the X chromosome in a single experiment. Compared to alternative genotyping technologies, the HuSNP assay reduces sample and reagent consumption while providing significant time and labor savings in sample preparation and data analysis. GeneChip platform users will benefit from the integration of reagent chemistries, protocols, software and instrumentation. Affymetrix collaborated with the Whitehead Institute/MIT Center for Genome Research to discover many of the SNPs represented in the new mapping assay. The Stanford Human Genome Center collaborated in mapping many of the SNPs. The study of individual genetic variation and its impact on the understanding and treatment of human disease has gained further momentum with the announcement by the National Institutes of Health (NIH) of an accelerated completion date of the rough-draft human genome sequence. More recently, The SNP Consortium, Ltd. was formed between leading academic centers and pharmaceutical companies to discover genetic variations, particularly SNPs, and to make those discoveries publicly available. The GeneChip HuSNP Mapping Assay is the first in a planned line of Affymetrix products designed to support applications in the fast-emerging field of genotyping. The GeneChip system consists of disposable DNA probe arrays containing oligonucleotide probe sequences on a chip, reagents for use with the arrays, a scanner and other instruments to process the probe arrays, and software to analyze and manage the genetic information. For more information about Affymetrix products for genetic analysis, the Company may be contacted in North America at 800-223-5281, in Europe at +44 (0) 7000 785 803, or on the web at www.affymetrix.com. All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, and market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection. These and other risk factors are discussed in Affymetrix' Annual Report on Form 10-K for the year ended December 31, 1998, Form 10-Q for the quarter ended March 31, 1999 and Form S-3 filed July 12, 1999. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks and HuSNP is a trademark used by Affymetrix, Inc.